Cargando…
Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury
The pathologic process of chronic phase traumatic brain injury is associated with spreading inflammation, cell death, and neural dysfunction. It is thought that sequestration of inflammatory mediators can facilitate recovery and promote an environment that fosters cellular regeneration. Studies have...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090825/ https://www.ncbi.nlm.nih.gov/pubmed/27857726 http://dx.doi.org/10.4103/1673-5374.191197 |
_version_ | 1782464458827759616 |
---|---|
author | Mashkouri, Sherwin Crowley, Marci G. Liska, Michael G. Corey, Sydney Borlongan, Cesar V. |
author_facet | Mashkouri, Sherwin Crowley, Marci G. Liska, Michael G. Corey, Sydney Borlongan, Cesar V. |
author_sort | Mashkouri, Sherwin |
collection | PubMed |
description | The pathologic process of chronic phase traumatic brain injury is associated with spreading inflammation, cell death, and neural dysfunction. It is thought that sequestration of inflammatory mediators can facilitate recovery and promote an environment that fosters cellular regeneration. Studies have targeted post-traumatic brain injury inflammation with the use of pharmacotherapy and cell therapy. These therapeutic options are aimed at reducing the edematous and neurodegenerative inflammation that have been associated with compromising the integrity of the blood-brain barrier. Although studies have yielded positive results from anti-inflammatory pharmacotherapy and cell therapy individually, emerging research has begun to target inflammation using combination therapy. The joint use of anti-inflammatory drugs alongside stem cell transplantation may provide better clinical outcomes for traumatic brain injury patients. Despite the promising results in this field of research, it is important to note that most of the studies mentioned in this review have completed their studies using animal models. Translation of this research into a clinical setting will require additional laboratory experiments and larger preclinical trials. |
format | Online Article Text |
id | pubmed-5090825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-50908252016-11-17 Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury Mashkouri, Sherwin Crowley, Marci G. Liska, Michael G. Corey, Sydney Borlongan, Cesar V. Neural Regen Res Invited Review The pathologic process of chronic phase traumatic brain injury is associated with spreading inflammation, cell death, and neural dysfunction. It is thought that sequestration of inflammatory mediators can facilitate recovery and promote an environment that fosters cellular regeneration. Studies have targeted post-traumatic brain injury inflammation with the use of pharmacotherapy and cell therapy. These therapeutic options are aimed at reducing the edematous and neurodegenerative inflammation that have been associated with compromising the integrity of the blood-brain barrier. Although studies have yielded positive results from anti-inflammatory pharmacotherapy and cell therapy individually, emerging research has begun to target inflammation using combination therapy. The joint use of anti-inflammatory drugs alongside stem cell transplantation may provide better clinical outcomes for traumatic brain injury patients. Despite the promising results in this field of research, it is important to note that most of the studies mentioned in this review have completed their studies using animal models. Translation of this research into a clinical setting will require additional laboratory experiments and larger preclinical trials. Medknow Publications & Media Pvt Ltd 2016-09 /pmc/articles/PMC5090825/ /pubmed/27857726 http://dx.doi.org/10.4103/1673-5374.191197 Text en Copyright: © Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Invited Review Mashkouri, Sherwin Crowley, Marci G. Liska, Michael G. Corey, Sydney Borlongan, Cesar V. Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury |
title | Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury |
title_full | Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury |
title_fullStr | Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury |
title_full_unstemmed | Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury |
title_short | Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury |
title_sort | utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury |
topic | Invited Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090825/ https://www.ncbi.nlm.nih.gov/pubmed/27857726 http://dx.doi.org/10.4103/1673-5374.191197 |
work_keys_str_mv | AT mashkourisherwin utilizingpharmacotherapyandmesenchymalstemcelltherapytoreduceinflammationfollowingtraumaticbraininjury AT crowleymarcig utilizingpharmacotherapyandmesenchymalstemcelltherapytoreduceinflammationfollowingtraumaticbraininjury AT liskamichaelg utilizingpharmacotherapyandmesenchymalstemcelltherapytoreduceinflammationfollowingtraumaticbraininjury AT coreysydney utilizingpharmacotherapyandmesenchymalstemcelltherapytoreduceinflammationfollowingtraumaticbraininjury AT borlongancesarv utilizingpharmacotherapyandmesenchymalstemcelltherapytoreduceinflammationfollowingtraumaticbraininjury |